A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.
Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...
Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.
A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
In surveys, parents of children with SMA and healthcare professionals in Sweden note the many ways the pandemic affected ...
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback